The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans

Pharmaceutical Research

Volumn 14, Issue 2, 1997, Pages 152-155

  Lave Th ^a   Dupin, S ^a   Schmitt, C ^a   Valles, B ^a   Ubeaud, G ^a   Chou, R C ^a   Jaeck, D ^a   Coassolo, Ph ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Clearance; Extraction ratio; Human hepatocytes; In vitro models; Pharmacokinetics

Indexed keywords

3 (5 DIPROPYLAMINOMETHYL 1,2,4 OXADIAZOL 3 YL) 8 FLUORO 5,6 DIHYDRO 5 METHYL 4H IMIDAZO[1,5 A][1,4]BENZODIAZEPIN 6 ONE; BOSENTAN; CAFFEINE; DIAZEPAM; DILTIAZEM; LORAZEPAM; MIBEFRADIL; MIDAZOLAM; MOFAROTENE; N METHYL DEXTRO ASPARTIC ACID; NALOXONE; OXAZEPAM; PHENAZONE; PROPRANOLOL; REMIKIREN; RO 48 8684; THEOPHYLLINE; TOLCAPONE; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; INFORMATION PROCESSING; LIVER CELL; LIVER METABOLISM; NORMAL HUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TECHNIQUE;

ADULT; AGED; BIOLOGICAL AVAILABILITY; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; HUMANS; LIVER; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 0030911863     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012036324237     Document Type: Article

References (24)

1. G. Desousa, N. Florence, B. Valles, P. Coassolo, and R. Rahmani. Cell Biol. Toxicol 11:147-153 (1995).
2. J. B. Houston. Biochem. Pharmacol. 47:1469-1479 (1994).
3. K. Zomorodi, D. J. Carlile, and J. B. Houston. Xenobiotica 25:907-916 (1995).
4. K. A. Hayes, B. Brennan, R. Chenery, and J. B. Houston. Drug Metab. Dispos. 23:349-353 (1995).
5. B. A. Hoener. Biopharm. Drug Dispos. 15:295-304 (1994).
6. T. Seddon, I. Michelle, and R. J. Chenery. Biochem. Pharmacol. 38:1657-1665 (1989).
7. G. Fabre, R. Rahmani, M. Placidi, J. Combalbert, J. Covo, J. P. Cano, C. Coulange, M. Ducros, and M. Rampai. Biochem. Pharmacol. 37:4389-4397 (1988).
8. M. Rowland, and T. Tozer. Lea and Febiger, Philadelphia, London, (1989).
9. P. Skett, C. Tyson, A. Guillouzo, and P. Maier. Biochem. Pharmacol. 50:280-5 (1995).
10. M. Spatzenegger, and W. Jaeger. Drug Metab. Rev. 27:397-417 (1995).
11. S. Kawasaki, Y. Sugiyama, T. Iga, M. Hanano, T. Beppu, M. Sugiura, K. Sanjo, and Y. Idezuki. Clin. Pharmacol. Ther. 44:217-224 (1988).
12. M. Bonati, R. Latini, G. Tognoni, J. F. Young, and S. Garattini. Drug Metab. Rev. 15:1355-83 (1984).
13. U. Klotz, K. H. Antonin, and P. R. Bieck. J. Pharmacol. Exp. Ther. 199:67-73 (1976).
14. P. Hoglund, and L. G. Nilsson. Ther. Drug Monit. 10:401-409 (1988).
15. H. Boxenbaum. J. Pharmacokinet. Biopharm. 10:411-426 (1982).
16. H. Allonen, G. Ziegler, and U. Klotz. Clin. Pharmacol. Ther. 30:653-661 (1981).
17. M. T. Smith, M. J. Eadie, and T. O. Brophy. Eur. J. Clin. Pharmacol. 19:271-278 (1981).
18. P. Heizmann, M. Eckert, and W. H. Ziegler. Br. J. Clin. Pharmacol. 16:43S-49S (1983).
19. J. P. Labaune. Masson, Paris, (1991).
20. J. Sonne, S. Loft, M. Dossing, A. Vollmer-Larsen, K. L. Olesen, M. Victor, F. Andreasen, and P. B. Andreasen. Eur. J. Clin Pharmacol. 35:385-389 (1988).
21. L. S. Olanoff, T. Walle, K. Walle, T. D. Cowart, and T. E. Gaffney. Clin. Pharmacol. Ther. 35:755-761 (1984).
22. G. A. Rongen, J. W. M. Lenders, P. Smits, and T. Thien. Clin. Pharmacokinet. 29:6-14 (1995).
23. F. Gaspari, and M. Bonati. Drug Metab. Rev. 22:179-207 (1990).
24. N. H. G. Holford. Clin. Pharmacokinet. 11:483-504 (1986).